The EPS projection of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for quarter ended 2016-09-30 is $-0.73. Last week, the projection for EPS was $-0.73 against target of $-0.73, a month earlier. While 2-months ago, this projection was $-0.73 versus forecast of $-0.73a quarter months earlier, posting a deviation of 0%.
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) posted that 18 days earlier, the share price was revised 0 times on upside. In addition, negative revisions were 3.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 0 and 0. While in last 120 and 90 days, positive revisions were 0, and 0, correspondingly.
The per-share earnings downgrade for OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) in the preceding 30 and 120 were 0 and 2. While in 60 and 90 days were 1, and 3, in that order.
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) EPS target was $-0.73 for the quarter closed 1. It was based on 4 calls. As on 2016-05-05 the EPS was $-0.9. The change was $-0.19, posting a deviation of -26.76%. The price projections gave a standard deviation of 0.18.
Quarterly Sales Estimates
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) sales prediction for the fiscal 2016 stands at $7.175 and the median estimate is at $7.175. Almost 2 analysts gave sales target.
Among this, the highest sales estimate is $9.45 while the lowest target is $4.9 showing standard deviation of 3.217%.
As many as 2 analysts have positive sales targets revision while 2 reduced sales estimates, posting a deviation of 0%.
Last month, 2 experts have positive sales number revision. Also, 2 research groups lowered the sales projections, posting a deviation of 0%.
A quarter ago, 2 hiked sales target and 2 reduced sales forecast, posting a deviation of -20.936%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...